{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.4","value":"139522.4"},{"groupId":"OG001","spread":"24.3","value":"142526.9"},{"groupId":"OG002","spread":"25.9","value":"135024.5"},{"groupId":"OG003","spread":"23.9","value":"137317.7"},{"groupId":"OG004","spread":"18.0","value":"142630.1"},{"groupId":"OG005","spread":"26.6","value":"113596.9"},{"groupId":"OG006","spread":"30.6","value":"119921.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"title":"c-KIT (C1D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.1","value":"110154.0"},{"groupId":"OG001","spread":"8.2","value":"99962.7"},{"groupId":"OG002","spread":"15.1","value":"94307.1"},{"groupId":"OG003","spread":"18.9","value":"99989.6"},{"groupId":"OG004","spread":"23.0","value":"121497.7"},{"groupId":"OG005","spread":"2.0","value":"71216.5"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG006","spread":"NA","value":"154558.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"}],"units":"Participants"}],"title":"c-KIT (C2D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"63.1","value":"7.8"},{"groupId":"OG001","spread":"71.1","value":"6.9"},{"groupId":"OG002","spread":"59.1","value":"8.3"},{"groupId":"OG003","spread":"6.0","value":"5.9"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG005","spread":"NA","value":"13.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"FGF (C1D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"68.9","value":"15.1"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG001","spread":"NA","value":"6.2"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG002","spread":"NA","value":"5.1"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG004","spread":"NA","value":"6.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"FGF (C2D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"245.7","value":"19.6"},{"groupId":"OG001","spread":"27.6","value":"8.9"},{"groupId":"OG002","spread":"36.9","value":"9.4"},{"groupId":"OG003","spread":"37.0","value":"10.5"},{"groupId":"OG004","spread":"6.2","value":"9.3"},{"groupId":"OG005","spread":"126.6","value":"13.7"},{"groupId":"OG006","spread":"29.7","value":"8.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"title":"PGF (C1D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"259.4","value":"54.6"},{"groupId":"OG001","spread":"74.9","value":"27.8"},{"groupId":"OG002","spread":"82.9","value":"37.4"},{"groupId":"OG003","spread":"113.8","value":"63.2"},{"groupId":"OG004","spread":"300.5","value":"30.3"},{"groupId":"OG005","spread":"840.1","value":"225.2"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG006","spread":"NA","value":"39.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"}],"units":"Participants"}],"title":"PGF (C2D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.5","value":"8086.8"},{"groupId":"OG001","spread":"25.0","value":"8180.0"},{"groupId":"OG002","spread":"15.6","value":"7280.6"},{"groupId":"OG003","spread":"7.7","value":"8574.9"},{"groupId":"OG004","spread":"4.6","value":"7439.8"},{"groupId":"OG005","spread":"30.0","value":"8179.2"},{"groupId":"OG006","spread":"18.3","value":"7842.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"title":"TIE2 (C1D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.5","value":"8340.1"},{"groupId":"OG001","spread":"11.5","value":"7788.8"},{"groupId":"OG002","spread":"22.7","value":"7650.6"},{"groupId":"OG003","spread":"17.4","value":"7894.1"},{"groupId":"OG004","spread":"28.2","value":"8026.6"},{"groupId":"OG005","spread":"32.0","value":"6824.4"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG006","spread":"NA","value":"8540.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"}],"units":"Participants"}],"title":"TIE2 (C2D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"133.8","value":"63.8"},{"groupId":"OG001","spread":"66.1","value":"46.1"},{"groupId":"OG002","spread":"98.0","value":"74.0"},{"groupId":"OG003","spread":"62.0","value":"82.9"},{"groupId":"OG004","spread":"39.0","value":"48.8"},{"groupId":"OG005","spread":"268.3","value":"62.2"},{"groupId":"OG006","spread":"46.6","value":"129.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"title":"VEGF-A (C1D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"140.6","value":"123.3"},{"groupId":"OG001","spread":"166.8","value":"77.2"},{"groupId":"OG002","spread":"126.0","value":"171.8"},{"groupId":"OG003","spread":"98.7","value":"179.4"},{"groupId":"OG004","spread":"40.4","value":"219.3"},{"groupId":"OG005","spread":"750.0","value":"1057.5"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG006","spread":"NA","value":"208.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"}],"units":"Participants"}],"title":"VEGF-A (C2D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.6","value":"121.4"},{"groupId":"OG001","spread":"84.7","value":"152.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"VEGF-C (C1D1)"},{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG000","spread":"NA","value":"105.9"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG001","spread":"NA","value":"339.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"title":"VEGF-C (C2D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"54.6","value":"354.2"},{"groupId":"OG001","spread":"20.5","value":"372.3"},{"groupId":"OG002","spread":"21.6","value":"394.6"},{"groupId":"OG003","spread":"43.9","value":"375.4"},{"groupId":"OG004","spread":"108.7","value":"645.4"},{"groupId":"OG005","spread":"12.1","value":"351.7"},{"groupId":"OG006","spread":"75.9","value":"370.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"title":"VEGF-D (C1D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"77.4","value":"434.6"},{"groupId":"OG001","spread":"43.0","value":"501.8"},{"groupId":"OG002","spread":"16.9","value":"448.6"},{"groupId":"OG003","spread":"14.4","value":"551.7"},{"groupId":"OG004","spread":"50.1","value":"501.4"},{"groupId":"OG005","spread":"51.1","value":"791.4"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG006","spread":"NA","value":"400.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"}],"units":"Participants"}],"title":"VEGF-D (C2D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"292.3","value":"394.5"},{"groupId":"OG001","spread":"174.4","value":"175.7"},{"groupId":"OG002","spread":"121.7","value":"224.4"},{"groupId":"OG003","spread":"113.7","value":"134.6"},{"groupId":"OG004","spread":"42.9","value":"95.8"},{"groupId":"OG005","spread":"130.8","value":"367.5"},{"groupId":"OG006","spread":"109.6","value":"173.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"title":"VEGFR-1 (C1D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"98.5","value":"87.5"},{"groupId":"OG001","spread":"709.9","value":"534.3"},{"groupId":"OG002","spread":"121.1","value":"93.8"},{"groupId":"OG003","spread":"231.3","value":"140.0"},{"groupId":"OG004","spread":"4.9","value":"69.4"},{"groupId":"OG005","spread":"14.6","value":"76.4"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG006","spread":"NA","value":"1811.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"}],"units":"Participants"}],"title":"VEGFR-1 (C2D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.6","value":"31451.9"},{"groupId":"OG001","spread":"20.6","value":"31745.8"},{"groupId":"OG002","spread":"15.8","value":"33724.8"},{"groupId":"OG003","spread":"17.6","value":"34993.1"},{"groupId":"OG004","spread":"12.1","value":"31682.1"},{"groupId":"OG005","spread":"14.7","value":"39342.8"},{"groupId":"OG006","spread":"6.0","value":"30780.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"title":"VEGFR-2 (C1D1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.9","value":"25099.6"},{"groupId":"OG001","spread":"21.6","value":"23059.9"},{"groupId":"OG002","spread":"1.0","value":"23502.8"},{"groupId":"OG003","spread":"15.1","value":"22154.3"},{"groupId":"OG004","spread":"42.9","value":"25385.9"},{"groupId":"OG005","spread":"68.5","value":"13621.6"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG006","spread":"NA","value":"26266.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"}],"units":"Participants"}],"title":"VEGFR-2 (C2D1)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"3"}],"units":"Participants"}],"description":"The following biomarker parameters were analyzed: proto-oncogene c-KIT (c-KIT), Fibroblast growth factor (FGF), Placental growth factor PGF), Angiopoietin-1 receptor (TIE2), Vascular endothelial growth factor A (VEGF-A), Vascular endothelial growth factor C (VEGF-C), Vascular endothelial growth factor D (VEGF-D), Vascular endothelial growth factor receptor 1 (VEGFR-1) and Vascular endothelial growth factor receptor 2 (VEGFR-2)). Only descriptive analysis performed.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG000","title":"Cohort 1: Rhabdomyosarcoma (RMS)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG001","title":"Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG002","title":"Cohort 3: Ewing Sarcoma/pPNET (Ewing)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG003","title":"Cohort 4 (Osteosarcoma)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG004","title":"Cohort 5: Measurable Neuroblastoma (mNeuroblastoma)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG005","title":"Cohort 6: Evaluable Neuroblastoma (eNeuroblastma)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG006","title":"Cohort 7 (Hepatoblastoma)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Biomarker set","reportingStatus":"POSTED","timeFrame":"predose Cycle 1 Day 1, Cycle 2 Day 1","title":"Summary for Plasma Biomarkers Levels on Cycle 1 Day 1 and Cycle 2 Day 1 by Cohort","type":"SECONDARY","unitOfMeasure":"picogram/milliliter (pg/mL)"}